Skip to content
Disclosery

SR One Capital Management, LP

Follow

13F filer, CIK 1910264, Redwood City, CA

SR One Capital Management, LP reported $1,039,007,705 across 15 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-12. Its ten largest share positions make up 95.11% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-347065

Period
2026-06-30
Reported value
$1.04B
Holdings
15
Top 10 weight
95.11%
New
3
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
AVLNnew+3,308,649$109M
ODTXnew+3,794,883$71M
MOBInew+1,986,072$26.6M
ORICadded+100,455$1.09M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ACLXexited-2,346,630-$269M
ORKAexited-430,330-$21.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001193125-26-347065, largest first. % of portfolio is the value over $1,039,007,705, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MANEVERADERMICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,401,868 shares; 2026Q2: 2,401,868 shares 2,401,868$295M28.42%0Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,911,539 shares; 2024Q4: 4,911,539 shares; 2025Q1: 4,911,539 shares; 2025Q2: 4,911,539 shares; 2025Q3: 4,911,539 shares; 2025Q4: 5,037,854 shares; 2026Q1: 5,037,854 shares; 2026Q2: 5,037,854 shares 5,037,854$128M12.31%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,048,951 shares; 2024Q4: 1,048,951 shares; 2025Q1: 1,048,951 shares; 2025Q2: 1,048,951 shares; 2025Q3: 2,038,763 shares; 2025Q4: 2,038,763 shares; 2026Q1: 2,038,763 shares; 2026Q2: 2,038,763 shares 2,038,763$111M10.7%0Timeline
AVLNAVALYN PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,308,649 shares 3,308,649$109M10.48%newTimeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 6,526,476 shares; 2024Q4: 6,526,476 shares; 2025Q1: 6,526,476 shares; 2025Q2: 6,526,476 shares; 2025Q3: 6,526,476 shares; 2025Q4: 6,526,476 shares; 2026Q1: 6,526,476 shares; 2026Q2: 6,526,476 shares 6,526,476$94.4M9.09%0Timeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,794,883 shares 3,794,883$71M6.83%newTimeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,959,896 shares; 2024Q4: 1,959,896 shares; 2025Q1: 1,959,896 shares; 2025Q2: 1,959,896 shares; 2025Q3: 1,959,896 shares; 2025Q4: 1,959,896 shares; 2026Q1: 1,959,896 shares; 2026Q2: 1,959,896 shares 1,959,896$55.2M5.31%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 4,514,929 shares; 2025Q3: 4,514,929 shares; 2025Q4: 4,514,929 shares; 2026Q1: 4,514,929 shares; 2026Q2: 4,615,384 shares 4,615,384$50M4.81%+100,455Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,016,822 shares; 2024Q4: 2,016,822 shares; 2025Q1: 3,127,933 shares; 2025Q2: 3,127,933 shares; 2025Q3: 2,113,933 shares; 2025Q4: 1,563,966 shares; 2026Q1: 1,563,966 shares; 2026Q2: 1,563,966 shares 1,563,966$42.2M4.06%0Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,012,903 shares; 2024Q4: 4,012,903 shares; 2025Q1: 4,012,903 shares; 2025Q2: 4,012,903 shares; 2025Q3: 4,012,903 shares; 2025Q4: 4,012,903 shares; 2026Q1: 4,012,903 shares; 2026Q2: 4,012,903 shares 4,012,903$32.1M3.09%0Timeline
MOBIMOBIA MED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,986,072 shares 1,986,072$26.6M2.56%newTimeline
NKTXNKARTA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,333,333 shares; 2024Q4: 3,333,333 shares; 2025Q1: 3,333,333 shares; 2025Q2: 3,333,333 shares; 2025Q3: 3,333,333 shares; 2025Q4: 3,333,333 shares; 2026Q1: 3,333,333 shares; 2026Q2: 3,333,333 shares 3,333,333$9.43M0.91%0Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 322,500 shares; 2025Q2: 322,500 shares; 2025Q3: 322,500 shares; 2025Q4: 641,022 shares; 2026Q1: 641,022 shares; 2026Q2: 641,022 shares 641,022$8.89M0.86%0Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 137,753 shares; 2026Q1: 137,753 shares; 2026Q2: 137,753 shares 137,753$4.6M0.44%0Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 747,750 shares; 2024Q4: 747,750 shares; 2025Q1: 747,750 shares; 2025Q2: 747,750 shares; 2025Q3: 747,750 shares; 2025Q4: 747,750 shares; 2026Q1: 747,750 shares; 2026Q2: 747,750 shares 747,750$1.29M0.12%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ACLXARCELLX INC2,346,630$269Mshares
ORKAORUKA THERAPEUTICS INC430,330$21.1Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-347065 base2026-08-12acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001193125-26-347065 Quarter ended 2026-06-302026-08-12acceptance time not in the bulk data set
13F-HR 0001193125-26-224136 Quarter ended 2026-03-312026-05-14acceptance time not in the bulk data set
13F-HR 0001193125-26-048808 Quarter ended 2025-12-312026-02-12acceptance time not in the bulk data set
13F-HR 0001193125-25-277769 Quarter ended 2025-09-302025-11-12acceptance time not in the bulk data set
13F-HR 0000950123-25-008422 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0000950123-25-004926 Quarter ended 2025-03-312025-05-13acceptance time not in the bulk data set
13F-HR 0000950123-25-002049 Quarter ended 2024-12-312025-02-13acceptance time not in the bulk data set
13F-HR 0000950123-24-011277 Quarter ended 2024-09-302024-11-13acceptance time not in the bulk data set
13F-HR 0000950123-24-008225 Quarter ended 2024-06-302024-08-13acceptance time not in the bulk data set
13F-HR 0001910264-24-000003 Quarter ended 2024-03-312024-05-13acceptance time not in the bulk data set
13F-HR 0001910264-24-000001 Quarter ended 2023-12-312024-02-12acceptance time not in the bulk data set
13F-HR 0001910264-23-000007 Quarter ended 2023-09-302023-11-13acceptance time not in the bulk data set
13F-HR 0001910264-23-000005 Quarter ended 2023-06-302023-08-10acceptance time not in the bulk data set
13F-HR/A 0001910264-23-000003 Quarter ended 2023-03-312023-05-19acceptance time not in the bulk data set
13F-HR 0001910264-23-000002 Quarter ended 2023-03-312023-05-09acceptance time not in the bulk data set
13F-HR 0001910264-23-000001 Quarter ended 2022-12-312023-02-08acceptance time not in the bulk data set
13F-HR 0001910264-22-000004 Quarter ended 2022-09-302022-11-08acceptance time not in the bulk data set
13F-HR 0001910264-22-000003 Quarter ended 2022-06-302022-08-02acceptance time not in the bulk data set
13F-HR 0001910264-22-000002 Quarter ended 2022-03-312022-05-10acceptance time not in the bulk data set
13F-HR 0001910264-22-000001 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set